Clinical Outcome of a Cohort of 63 Patients with Hepatocellular   Carcinoma Treated with Octreotide

C. Rabe; T. Pilz; H. P. Allgaier; U. Halm; C. Straßer; M. Wettstein; T. Sauerbruch; W. H. Caselmann; null German multicentric Octreotide study group

doi:10.1055/s-2002-32129

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2002; 40(6): 395-400
DOI: 10.1055/s-2002-32129

Originalarbeit

Clinical Outcome of a Cohort of 63 Patients with Hepatocellular Carcinoma Treated with Octreotide

Klinische Resultate einer Octreotidbehandlung bei 63 Patienten mit hepatozellulärem KarzinomC. Rabe¹ , T. Pilz¹ , H. P. Allgaier² , U. Halm³ , C. Straßer⁴ , M. Wettstein⁵ , T. Sauerbruch¹ , W. H. Caselmann¹ , German multicentric Octreotide study group

¹Medizinische Klinik I, University of Bonn
²Medizinische Klinik, Abteilung Innere Medizin II, University of Freiburg
³Medizinische Klinik II, University of Leipzig
⁴III. Medizinische Klinik, Zentralklinikum Augsburg
⁵Klinik für Gastroenterologie, Hepatologie und Infektiologie, University of Düsseldorf

Abstract

Unresectable hepatocellular carcinoma (HCC) are associated with a poor prognosis. Recently, one controlled study reported a strikingly prolonged survival of patients with HCC who were treated with octreotide. Until other randomised controlled trials become available, this multicentric retrospective study therefore assesses the outcome of HCC-patients who received octreotide treatment.

63 patients (53males, 10 females) who had been treated with octreotide at 13 participating German centres were included in the analysis. In 54 cases liver cirrhosis was present (25 Child-Pugh A, 20 Child-Pugh B, 7 Child-Pugh C, 2 unknown). The liver disease was associated with alcohol abuse in 19 patients, alcohol and viral hepatitis in four patients, while 12 patients had only markers of past or present hepatitis B infection, 11 patients suffered of chronic hepatitis C infection, and four patients were seropositive for both hepatitis B and hepatitis C markers. The Okuda stage was stage I in 23, stage II in 33, and stage III in 7 patients.

The patients initially received octreotide as a long-acting release formula (20-30 mg/month) in 43 cases or through subcutaneous injection (dose 3 x 50-3 x 300 ug/day) in the remaining cases. 11 of the patients receiving subcutaneous treatment were later converted to the long-acting release form of the drug.

At three months, a partial remission was achieved in two patients, while 22 tumours showed no change and 26 tumours progressed. At six months, 11 tumours showed no change, while 15 tumours progressed.

The patients’ median survival was 9 months (Okuda stage I 16 months, stage II 9 months, stage III 4 months). In conclusion, octreotide treatment did not result in markedly prolonged survival in this retrospective series of 63 patients.

Zusammenfassung

Das unresezierbare hepatozelluläre Karzinom (HCC) hat eine schlechte Prognose. Eine kürzlich veröffentlichte Studie hat einen deutlichen Überlebensvorteil octreotidbehandelter Patienten gezeigt. Bevor weitere randomisiert-kontrollierte Studien zur Verfügung stehen, untersucht diese retrospektive, multizentrische Studie den Verlauf octreotidbehandelter Patienten.

63 Patienten (53 Männer, 10 Frauen), die an 13 teilnehmenden deutschen Zentren mit Octreotid behandelt worden waren, wurden in die Studie aufgenommen. 54 der Patienten waren Leberzirrhotiker (25 Child-Pugh A, 20 Child-Pugh B, 7 Child-Pugh C, 2 unbekannt). Ursache der Lebererkrankung war ein Alkoholabusus bei 19 Patienten und eine Kombination aus Alkohol und Virushepatitis bei vier Patienten. 12 Patienten wiesen Marker auf, die auf einen Kontakt mit dem Hepatitis-B-Virus hinwiesen, 11 Patienten waren mit Hepatitis C infiziert und vier Patienten wiesen sowohl Hepatitis-B- als auch Hepatitis-C-Marker auf. Das Okuda-Stadium war I bei 23, II bei 33 und III bei 7 Patienten.

43 der Patienten erhielten Octreotid in Depotform (20-30 mg/Monat) und die übrigen Patienten erhielten subkutane Injektionen (Dosis 3 x 50-3 x 300 ug/Tag). 11 der Patienten, die anfangs subkutane Injektionen erhielten, wurden später auf Octreotid in Depotform umgestellt.

Nach drei Monaten konnten ein partielles Ansprechen bei zwei Patienten, keine Veränderung bei 22 Patienten und ein Tumorprogress bei 26 Patienten festgestellt werden. Nach sechs Monaten zeigten 11 Tumoren keine Veränderung und 15 Tumoren zeigten einen Progress. Das mediane Patientenüberleben betrug 9 Monate (Okuda-Stadium I 16 Monate, Stadium II 9 Monate, Stadium III 4 Monate).

Zusammenfassend konnte in der vorliegenden retrospektiven Serie von 63 Patienten kein deutlich verlängertes Überleben octreotidbehandelter Patienten aufgezeigt werden.

Key words

Cirrhosis - Hepatocellular Carcinoma - Prognosis - Liver Transplantation - Octreotide

Schlüsselwörter

Leberzirrhose - Hepatozelluläres Karzinom - Prognose - Lebertransplantation - Octreotid

Full Text

References

1 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340 745-750
2 El-Serag H B, Mason A C. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000; 160 3227-3230
3 Rabe C, Caselmann W H. Interaction of Hepatitis B virus with cellular processes in liver carcinogenesis. Crit Rev Clin Lab Sci. 2000; 37 407-429
4 Caselmann W H, Alt M. Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. J Hepatol. 1996; 24 61-66
5 Kubicka S, Rudolph K L, Hanke M. et al . Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver. 2000; 20 312-318
6 Rabe C, Pilz T, Klostermann C. et al . Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroentero. 2001; 7 208-215
7 Petry W, Heintges T, Hensel F. et al . Hepatozelluläres Karzinom in Deutschland. Epidemiologie, Ätiologie, Klinik und Prognose bei 100 konsekutiven Patienten einer Universitätsklinik. Z Gastroenterol. 1997; 35 1059-1067
8 Rabe C, Heller J, Sauerbruch T, Caselmann W H. Leberzirrhose - Teil 1: Pathogenese und Diagnostik. Dtsch Med Wochenschr. 2001; 126 975-977
9 Schoniger-Hekele M, Muller C, Kutilek M. et al . Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001; 48 103-109
10 Allgaier H P, Deibert P, Olschewski M. et al . Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - a single-center analysis including 132 patients. Int J Cancer. 1998; 79 601-605
11 Vogl T J, Eichler K, Straub R. et al . Laser-induced thermotherapy of malignant liver tumors: general principals, equipment(s), procedure(s) - side effects, complications and results. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: technique and prospective results. Eur J Ultrasound. 2001; 13 117-127
12 Giorgio A, Tarantino L, Mariniello N. et al . Percutaneous ethanol injection under general anesthesia for hepatocellular carcinoma: 3 year survival in 112 patients. Eur J Ultrasound. 1998; 8 201-206
13 Kouroumalis E, Skordilis P, Thermos K. et al . Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998; 42 442-447
14 Raderer M, Hejna M H, Muller C. et al . Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol. 2000; 16 1197-1201
15 Allgaier H P, Becker G, Blum H E. Therapiestudie des hepatozellulären Karzinoms mit Octreotid („HECTOR”). Dtsch Med Wochenschr. 2000; 125 320
16 Risse J H, Grunwald F, Kersjes W. et al . Intraarterial HCC therapy with I-131-Lipiodol. Cancer Biother Radiopharm. 2000; 15 65-70
17 Miller A B, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47 207-214
18 Raderer M, Hejna M H, Kurtaran A. et al . Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide. Am J Gastroenterol. 1999; 94 278-279
19 Schoniger-Hekele M, Müller C, Kutilek M. et al . Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol. 2000; 12 941-948
20 Liu C L, Fan S T, Ng I O. et al . Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol. 2000; 95 218-222
21 Trevisani F, De Notariis S, Rossi C, Bernardi M. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies?. J Clin Gastroenterol. 2001; 32 383-389
22 Riestra S, Rodriguez M, Delgado M. et al . Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol. 1998; 26 200-203
23 Reubi J C, Zimmermann A, Jonas S. et al . Regulatory peptide receptors in human hepatocellular carcinomas. Gut. 1999; 45 766-774
24 Diaconu C C, Szathmari M, Keri G, Venetianer A. Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232. Br J Cancer. 1999; 80 1197-1203

Dr. C. Rabe

Sigmund-Freud-Straße 25

53105 Bonn

Germany

Email: Rabe@uni-bonn.de